% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Oeckl:285455,
author = {Oeckl, Patrick and Abu-Rumeileh, Samir and Weise,
Christopher M and Otto, Markus},
collaboration = {Initiative, Alzheimer’s Disease Neuroimaging},
title = {{L}ongitudinal changes of blood β-synuclein in cognitively
unimpaired, mild cognitive impairment and sporadic
{A}lzheimer´s disease.},
journal = {Alzheimer's research $\&$ therapy},
volume = {18},
number = {1},
issn = {1758-9193},
address = {London},
publisher = {BioMed Central},
reportid = {DZNE-2026-00237},
pages = {45},
year = {2026},
abstract = {β-Synuclein is an emerging synaptic blood biomarker for
Alzheimer´s disease (AD) and correlates with cognitive
impairment, brain atrophy and amyloid/tau pathology.
Longitudinal data from individual patients are missing so
far but are important to evaluate how changes of
β-synuclein might be used in early diagnosis, prediction,
disease progression and treatment monitoring.In this
observational study, we investigated serum β-synuclein by
immunoprecipitation-mass spectrometry (IP-MS) in 463
participants from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI) including clinically diagnosed cognitively
unimpaired, mild cognitive impairment (MCI) and AD dementia
subjects with ≥ 1 follow-up samples for 235 individuals
and clinical follow-up for up to 19 years. CSF AD biomarker
levels were available for 194 participants.Participants
$(40.0\%$ female, n = 185) had a mean (± SD) age of 76.2 ±
6.7 years. The cross-sectional group comparison yielded
higher β-synuclein levels in MCI and AD dementia compared
with CU and in AD dementia vs MCI patients. Mean follow-up
time of longitudinal serum samples was 2.3 ± 1.2 years. The
longitudinal data indicate that β-synuclein levels are
dynamic during all stages of the AD continuum (CU, MCI,
dementia) with substantial inter-individual variation.
β-Synuclein predicted MCI-to-dementia conversion and future
cognitive decline and it performed better in discrimination
of AD dementia patients than CSF neurogranin.Our
longitudinal data support the use of serum β-synuclein
levels for prediction of future cognitive decline and
MCI-to-dementia conversion but needing confirmation. Further
studies with biologically and clinically defined
participants must verify the trajectories of β-synuclein
during the AD continuum.The online version contains
supplementary material available at
10.1186/s13195-026-01973-1.},
keywords = {Blood biomarker (Other) / Longitudinal observation (Other)
/ Mild cognitive impairment (Other) / Sporadic Alzheimer´s
disease (Other) / Synaptic degeneration (Other) /
β-synuclein (Other)},
cin = {AG Öckl},
ddc = {610},
cid = {I:(DE-2719)5000073},
pnm = {353 - Clinical and Health Care Research (POF4-353)},
pid = {G:(DE-HGF)POF4-353},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41673920},
pmc = {pmc:PMC12930813},
doi = {10.1186/s13195-026-01973-1},
url = {https://pub.dzne.de/record/285455},
}